IBIS II: A randomised phase III trial of anastrozole for breast cancer prevention in postmenopausal women at high risk. [ 2009 - 2013 ]

Research Grant

Researchers: Prof John Forbes (Principal investigator) ,  Prof Alan Coates ,  Prof Christobel Saunders ,  Prof Frances Boyle ,  Prof Gregory Mann
View all 6 related researchers

Brief description The IBIS II trial builds on the successful IBIS 1 breast cancer (BC) prevention trial in determining whether a chemopreventive strategy towards BC is beneficial. Women who are postmenopausal with an increased risk of BC are randomised to receive either anastrozole (an aromatase inhibitor) or placebo as a daily tablet. Neither the woman nor her clinician know which treatment has been allocated (double blind study). IBIS 2 has the potential to benefit many higher risk women worldwide.

Funding Amount $AUD 1,732,559.35

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant